Castration: the first contraceptive implant for dogs

With its veterinary laboratory authoritative in canine reproduction, Virbac is offering an innovative concept: an implant the size of an electronic chip, designed to suspend the fertility of sexually mature male dogs for a minimum of 6 months, and in a completely safe way.

An original deslorelin-based technology
This implant on veterinary prescription has a direct influence on the reproductive hormones through the use of deslorelin: continuous administration in low doses blocks the production of hormones. This gradually leads to failed testosterone synthesis and to a loss of the reproductive function. This testosterone-dependent infertility is characterised by at least five factors:

• A reduction in the volume of ejaculate
• A reduction in sperm production
• A reduction in sperm motility
• An increase in sperm anomalies
• A reduced libido

A single painless subcutaneous implantation
The recommended dosage is one implant (deslorelin acetate 4.7 mg) per dog, irrespective of the size of the dog. Without the need for anaesthesia, the implantation is performed by a single subcutaneous injection between the dog's shoulder blades, for a targeted effect. The active pharmaceutical ingredient gradually diffuses and continues to do so for at least 6 months. On first implantation, functional infertility is reached after 6 weeks.

Safe and effective long-term fertility control
Using an implant every 6 months provides effective and safe long-term fertility control. The implantation causes a reduction in sexual hormones, which results in a fall in testosterone, leading to an absence of sperm cells . During clinical studies, no significant effects were detected in relation to general state, behaviour, food consumption, weight or in blood tests. A return to normal can be identified following termination of the treatment, irrespective of the duration of treatment.

A reversible effect
The effect is reversible after one or more implantations. The majority of dogs will once again have sperm with normal characteristics the year following treatment.

Pharmapack congress: a Virbac packaging rewarded
Companion animals: Virbac is releasing a new external parasiticide onto the European market
Otitis externa in dogs: Virbac honoured at the “Pharmapack Awards 2009”
News
Effective and practical
Key products
Latest products
Dedicated services
Packagings differ from country to country

Click here to find the best contact in your living area
Ok
ANNUAL REPORT 2012
Discover the chairman's message
CONTACT

 VIRBAC WORLDWIDE